Scientific instruments manufacturer, Bruker Corporation (BRKR), launched its new biological microscopic technology – BioScope Resolve – at the Sixth AFM BioMed Conference that was held in San Diego, CA from Dec 13–17, 2014.
This new technology is designed to synchronize with the leading inverted optimal microscope (IOM) brands and offers the highest resolution molecular and cellular imaging for all types of biological samples.
This new biological atomic force microscope (bioAFM) from Bruker incorporates the company's proprietary PeakForce Tapping technology, which enables researchers to use reduced imaging forces, thereby protecting fragile biological samples with no decrease in image resolution. BioScope Resolve employs this expertise to provide a full array of accessories that preserves the integrity of delicate samples.
Moreover, BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets, which holds substantial value in life sciences research.
Notably, through the BioScope Resolve system, bioAFM analysis can directly associate high-resolution molecular structures with functions on the same cell. With this, Bruker has established a new benchmark for high-resolution imaging and cell mechanics characterization capabilities that are fully integrated with optimal microscopy.
With revenues worth nearly $2 billion, Bruker is a renowned manufacturer of high-end analytical instruments serving the pharma/biotech and clinical diagnostic markets. We believe the launch of the new age bioAFM system will duly bolster investor confidence in the company.
Zacks Rank
Currently, Bruker holds a Zacks Rank #4 (Sell). Some better-ranked companies worth reckoning in the medical sector instead are Affymetrix Inc. (AFFX), Biogen Idec Inc. (BIIB) and ANI Pharmaceuticals, Inc. (ANIP). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment